Department of Molecular Biology and Genetics, Faculty of Science, Istanbul University, Istanbul, Turkey.
Department of Molecular Biology and Genetics, Faculty of Arts and Sciences, Yeni Yuzyil University, Istanbul, Turkey.
Kidney Blood Press Res. 2017;42(6):1322-1337. doi: 10.1159/000485987. Epub 2017 Dec 15.
BACKGROUND/AIMS: MiRNAs transpire as promising elements in molecular medicine for the identification of new diagnostic, prognostic and targeting therapeutic biomarkers. This study consisted of four steps: First, to investigate one or a group of specific diagnostic miRNAs for Systemic Lupus Erythematosus (SLE) disease in patients with and without renal involvement, second, to identify cytokines genes' expression profiling, third, comparing the profiles with related amounts in the serum and finally, to study target-gene-mediated functional roles of miRNAs, which have been correlated to disease development and progression.
In order to use in microarray assays total RNA and miRNAs were isolated from blood and serum samples that were obtained from 16 SLE patients (9 with renal involvement and 7 without renal involvement). Taking coexistence of factors such as hypocomplementemia, positive ANA and anti-DNA into account, obtained data were processed. For each differentially expressed miRNA, potential target genes were predicted by microRNAorg, TargetScan and PITA prediction tools. Obtained mRNA profiling data were interrogated for the target genes. MiRNA and mRNA microarray results were confirmed by QRT-PCR. Finally, the amounts of cytokines were measured by multiplex ELISA method.
The results of study showed that among differentially expressed miRNAs in SLE patients with renal involvement compared to those without renal involvement, hsa-miR-766-3p, may play pivotal roles in PI3K-AKT-mTOR pathway. In addition according to the obtained data it is suggested that blood-borne proinflammatory cytokines such as IL-4, IL-6 and TNF-α alongside with disease stage and severity may contribute to this differential expression of these miRNA which may be leading to insulin resistance. Finally, hsa-miR-621, which was differentially expressed in hypertensive SLE patients without renal involvement and a positive ANA test with its predicted target gene "Kallikrein-related peptidase 9" may play a role in the pathophysiology of hypertension in SLE.
We reported some human miRNAs which were differentially expressed in SLE patients according to disease activity and renal involvement. Larger studies are necessary to confirm our findings and detect further biomarkers.
背景/目的:miRNAs 在分子医学中作为有前途的元素出现,可用于鉴定新的诊断、预后和靶向治疗生物标志物。本研究包括四个步骤:首先,研究系统性红斑狼疮(SLE)患者和无肾受累患者中一种或一组特定的诊断性 miRNAs;其次,鉴定细胞因子基因的表达谱;第三,比较与血清中相关量的关系;最后,研究与疾病发展和进展相关的 miRNA 靶基因介导的功能作用。
为了在微阵列分析中使用,从血液和血清样本中分离总 RNA 和 miRNAs,这些样本来自 16 名 SLE 患者(9 名有肾受累,7 名无肾受累)。考虑到低补体血症、ANA 阳性和抗 DNA 等因素的共存,处理获得的数据。对于每个差异表达的 miRNA,通过 microRNAorg、TargetScan 和 PITA 预测工具预测潜在的靶基因。对获得的 mRNA 表达谱数据进行靶基因检测。通过 QRT-PCR 验证 miRNA 和 mRNA 微阵列结果。最后,通过多重 ELISA 法测量细胞因子的量。
研究结果表明,在有肾受累的 SLE 患者与无肾受累的患者相比,hsa-miR-766-3p 可能在 PI3K-AKT-mTOR 途径中发挥关键作用。此外,根据获得的数据,提示血液来源的促炎细胞因子,如 IL-4、IL-6 和 TNF-α,以及疾病阶段和严重程度,可能导致这些 miRNA 的差异表达,这可能导致胰岛素抵抗。最后,在无肾受累的高血压 SLE 患者和 ANA 阳性患者中差异表达的 hsa-miR-621 及其预测靶基因“激肽释放酶相关肽酶 9”可能在 SLE 高血压的病理生理学中发挥作用。
我们报告了一些在 SLE 患者中根据疾病活动和肾受累差异表达的人类 miRNAs。需要更大的研究来证实我们的发现并检测进一步的生物标志物。